Home >
World Psoriasis Day 2019
2019/10/29
Today, IFPA presents World Psoriasis Day, as an annual day dedicated to people with psoriasis and/or psoriatic arthritis. It has been celebrated on October 29 for more than a decade. On World Psoriasis Day, our member associations and their supporters organise activities around the world to raise awareness of psoriasis.
To see examples of all the activities our members put on in around the world last World Psoriasis Day, visit worldpsoriasisday2018.com.
Aim of World Psoriasis Day
World Psoriasis Day is dedicated to people living with psoriasis or psoriatic arthritis. On October 29, we aim to address their needs:
Raise awareness
Psoriasis affects over 125 million people around the world – not just physically, but also socially, emotionally and financially. World Psoriasis Day aims to raise the profile of this debilitating disease and increase awareness of the effect it has on people’s lives.
Spread information
For many, psoriasis is still a relatively unknown disease. On World Psoriasis Day, IFPA spreads information about psoriasis, dispel common myths and answer questions. They also inform patients about their own condition, so they can feel empowered to speak about it.
Improve access to treatment
On World Psoriasis Day, IFPA lobby to give people with psoriasis better access to appropriate, affordable treatment. That’s why they specifically address key health decision-makers like national governments, policy-makers and healthcare providers that day.
Give the psoriasis community a voice
Many people living with psoriasis may struggle to get the world to listen to their needs. World Psoriasis Day is an opportunity for the psoriasis community to speak out from a common platform – and have its voice heard.
Are there special World Psoriasis Day activities?
Yes! Each year, IFPA member associations organise a wide variety of World Psoriasis Day activities – from small gatherings to large-scale events. Examples of activities include:
Awareness-raising walks or running events
Free information events for the general public
Lectures or seminars held by medical professionals
Handing out flyers and brochures in public places
Drawing competitions
Sending out WPD postcards
Free psoriasis assessment and consultations at hospitals
Activities for children and youth
Photo exhibitions with psoriasis-related themes
Radio or TV interviews with patient leaders or medical experts
Fundraising barbecues, get-togethers or concerts
Outdoor yoga sessions for people with psoriasis
Coverage of World Psoriasis Day by local or national media
Can I join World Psoriasis Day?
Of course! World Psoriasis Day is open to anyone – whether you have psoriasis yourself, know someone who does or simply want to support people living with psoriasis.
To be part of World Psoriasis Day, you can:
Contact your national psoriasis association to find out about their plans for October 29.
Organise an activity yourself. Perhaps your national association isn’t planning anything or you live in a country without an active psoriasis association? Don’t let this stop you! Organising a workshop, an awareness-raising walk, or simply handing out flyers can be a great way to let your community know about World Psoriasis Day. If you organise something, we’d love to hear about it! That way, IFPA can help promote your activity and share some pictures afterwards for our global audience.
Follow IFPA on Facebook or Twitter to get the latest updates on IFPA’s World Psoriasis Day campaigns and plans.
Spread the word about World Psoriasis Day, wear orange and blue on October 29, or reach out to someone from the psoriasis community to let them know you are there for them.
SOURCE: https://ifpa-pso.com/our-actions/world-psoriasis-day/
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Off-label studies on apremilast in dermatology: a review.
Maloney NJ et al.
Off-label studies on apremilast in dermatology: a review.
J Dermatolog Treat.
2020 Mar , 31, (2):131-140.
Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify (...)
see on pubmed
Our ambition in a changing landscape of psoriasis treatments.
van de Kerkhof PCM et al.
Our ambition in a changing landscape of psoriasis treatments.
J Dermatolog Treat.
2020 Mar , 31, (2):105-107.
CARD14/CARMA2sh and TANK differentially regulate poly(I:C)-induced inflammatory reaction in keratinocytes.
J. Cell. Physiol..
2020 Mar , 235, (3):1895-1902.
CARD14/CARMA2sh (CARMA2sh) is a scaffold protein whose mutations are associated with the onset of human genetic psoriasis and other inflammatory skin disorders. Here we show that the immunomodulatory adapter protein TRAF family member-associated NF-κB activator (TANK) forms a complex with CARMA2sh and MALT1 in a human keratinocytic cell line. We also show that CARMA2 and TANK are individually required to activate the nuclear factor κB (NF-κB) response following exposure to (...)
see on pubmed
on Atopic Dermatitis
Off-label studies on apremilast in dermatology: a review.
Maloney NJ et al.
Off-label studies on apremilast in dermatology: a review.
J Dermatolog Treat.
2020 Mar , 31, (2):131-140.
Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify (...)
see on pubmed
Atopic dermatitis induces anxiety- and depressive-like behaviors with concomitant neuronal adaptations in brain reward circuits in mice.
Prog. Neuropsychopharmacol. Biol. Psychiatry.
2020 Mar 02, 98:109818.
Clinically, it has been reported that atopic dermatitis (AD) has been linked with negative emotional problems such as depression and anxiety, thereby reducing the quality of life, but little is known about the molecular mechanism that underlies AD-associated emotional impairments. We sought to determine whether AD could induce anxiety- and depressive-like symptoms in mice and to identify pertinent signaling changes in brain reward circuitry. AD-like lesions were induced by the repeated (...)
see on pubmed
Efficacy and safety of indigo naturalis ointment in Treating Atopic Dermatitis: A randomized clinical trial.
J Ethnopharmacol.
2020 Mar 25, 250:112477.
Indigo naturalis, a herbal medicine with a history of use dating back to ancient times, may be a good alternative topical treatment for atopic dermatitis (AD).
see on pubmed
